You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed/refractory Waldenström macroglobulinemia

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory Trial

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • +2 more
  • (no location specified)
Jul 18, 2023

Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt

Not yet recruiting
  • Relapsed/Refractory Waldenstrom Macroglobulinemia
  • +3 more
  • Brexucabtagene Autoleucel
  • +2 more
  • (no location specified)
Sep 8, 2022

Waldenström's Macroglobulinemia (WM) Trial in China (Zanubrutinib)

Completed
Has Results
  • Waldenström's Macroglobulinemia (WM)
  • Beijing, Beijing, China
  • +10 more
Mar 7, 2022

Waldenstrom's Macroglobulinemia Trial in Boston (Everolimus, Rituximab, Bortezomib)

Terminated
Has Results
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Apr 22, 2021

Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent, Mantle Cell Lymphoma Refractory Trial in Orange,

Recruiting
  • Follicular B-cell Non-Hodgkin's Lymphoma
  • +7 more
  • MB-106
  • Orange, California
  • +3 more
Nov 1, 2022

Patients Previously Treated WithMustang Bio CAR-T Cell

Enrolling by invitation
  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
  • +10 more
  • Prior MB-102 CAR-T cell investigational product.
  • Prior MB-106 CAR-T cell investigational product.
  • Duarte, California
  • +4 more
Dec 8, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL) Trial in Manchester,

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +7 more
  • Manchester, United Kingdom
  • +2 more
Aug 11, 2022

CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma Trial in Cincinnati, Columbus, Salt Lake City (LP-168)

Recruiting
  • CLL/SLL
  • +6 more
  • Cincinnati, Ohio
  • +2 more
May 7, 2022

Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)

Recruiting
  • Grade 3a Follicular Lymphoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Atlanta, Georgia
  • +1 more
May 31, 2022

Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Huntsville, Bethesda (Ublituximab,

Terminated
  • Non-Hodgkins Lymphoma
  • +6 more
  • Huntsville, Alabama
  • +1 more
May 5, 2022

Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

Completed
  • Multiple Myeloma
  • +7 more
  • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 2, 2022

Waldenstrom's Macroglobulinemia Trial in Boston (Bortezomib, Rituximab)

Completed
Has Results
  • Waldenstrom's Macroglobulinemia
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Oct 6, 2020

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,

Completed
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +8 more
  • PI3K inhibitor BKM120
  • +3 more
  • Atlanta, Georgia
  • +1 more
Jun 27, 2022

Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in United States

Recruiting
  • Relapsed/Refractory B-cell Lymphomas
  • +11 more
  • CLBR001 and SWI019
  • Duarte, California
  • +7 more
Jul 26, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia Trial in Australia,

Recruiting
  • Follicular Lymphoma
  • +7 more
  • Louisville, Kentucky
  • +4 more
Mar 11, 2022

Waldenstrom's Macroglobulinemia Trial in Denver, Boston (LBH589)

Completed
Has Results
  • Waldenstrom's Macroglobulinemia
  • Denver, Colorado
  • +1 more
Jan 10, 2021

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM) Trial in United States

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +6 more
  • Duarte, California
  • +10 more
Jul 14, 2022

Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma Trial in San Francisco (Fludarabine, Cyclophosphamide,

Recruiting
  • Refractory Non-Hodgkin Lymphoma
  • +8 more
  • San Francisco, California
    University of California, San Francisco
May 2, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +22 more
  • Scottsdale, Arizona
  • +1 more
Aug 10, 2021

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
Has Results
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +20 more
  • Scottsdale, Arizona
  • +1 more
May 6, 2022

Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,

Recruiting
  • Waldenstrom Macroglobulinemia
  • +8 more
  • Iopofosine I 131 single dose
  • +2 more
  • Redlands, California
  • +42 more
Dec 30, 2022

Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)

Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • Changchun, China
  • +5 more
Jan 27, 2023

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +20 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Chronic Lymphocytic Leukemia Trial in Ann Arbor (Pacritinib)

Terminated
  • Lymphoma, T-Cell, Cutaneous
  • +6 more
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Jan 20, 2021